Kálmán Tóth

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9

Detection and isolation of cell-derived microparticles are compromised by protein complexes resulting from shared biophysical parameters

Bence György, Károly Módos, Éva Pállinger et al. · Blood · 2010 · 403 citations · Full text

Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease

Klara Magyar, Róbert Halmosi, Anita Pálfi et al. · Clinical Hemorheology and Microcirculation · 2012 · 357 citations

Plasma viscosity: A forgotten variable

Gábor Késmárky, P. Kenyeres, Miklós Rábai et al. · Clinical Hemorheology and Microcirculation · 2008 · 315 citations

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10